---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-105548"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:52:20.900005+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# TELA Bio appoints William Plovanic to board; expands board to seven members

## Summary
- Board increased from six to seven members; Plovanic appointed as Class I director through 2026 annual meeting.
- Plovanic is Managing Director, Healthcare Equity Research at Canaccord Genuity; also former CEO/CFO of Obalon Therapeutics.
- Received initial equity grant: option for 17,550 shares (36-month vest) and RSU for 11,925 shares (3-year vest).
- Annual board retainer of $45,000; will receive annual equity awards starting at 2026 meeting (11,700 options + 7,950 RSUs).
- Plovanic is independent under Nasdaq rules; no related party transactions disclosed.

## SEC filing metadata
- accession: 0001104659-25-105548
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465925105548/0001104659-25-105548-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465925105548/tm2530000d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-105548
- JSON: https://secwatch.observer/filing/0001104659-25-105548.json
- Plain text: https://secwatch.observer/filing/0001104659-25-105548.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.